ASTM 100% 3.031 02/09/00
Aastrom Biosciences, Inc: (From MSN)
Development-stage Aastrom Biosciences' automated cell therapy systems are designed to replace human cells damaged by cancer chemotherapy. Its AastromReplicell, a cell production system being tested for approval in the US and Europe, grows cells in laboratory conditions; these can be used to replace blood cells, bone marrow cells, and immune cells. The system is designed to be less costly, faster, and less invasive than such traditional cell-replacement methods as blood transfusions and bone marrow transplants. The company is also developing the Aastrom Gene Loader, through which therapeutic genes can be transferred into target cells. Cobe Laboratories, which owns 20% of Aastrom, will market the CPS worldwide.
Float 7.50
Institutional Interest 11.95
Average Vol .76
Vol 2/1 483,100
Vol 2/2 844,300
Vol 2/3 536,100
Vol 2/7 7,334,500
Vol So far today 3,530,000
This is another one I bought last week that immediately went down :0) Price and Barchart rating is same as previous post...mostly down until yesterday. The volume has increased so much though, I'm holding to see what happens. (Also still holding AMSI) I think both are risky.
|
